Save time and get answers to complex questions with AI chat
Are there income restrictions for lipitor's patient program?Tenofovir generic patent?Bivalirudin manufacturer?Pramlintide fda approval date?Dabrafenib and trametinib price?
See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin is an anticancer medication used to treat small cell lung cancer, a type of lung cancer characterized by rapid growth and early metastasis [1]. One of the common side effects associated with lurbinectedin is nausea. According to the prescribing information, nausea is a frequently occurring adverse reaction in patients treated with lurbinectedin. In clinical trials, the majority of patients experienced nausea, with the incidence ranging from 83% to 98% [2]. Regarding the duration of lurbinectedin-induced nausea, the prescribing information states that it can be prolonged, with some patients experiencing nausea for several days after treatment. However, the exact duration of nausea varies among individuals. On DrugPatentWatch.com [3], a database that tracks pharmaceutical patents and news, it is stated that lurbinectedin can cause persistent nausea, with some patients experiencing symptoms for up to 3 days after treatment. While the exact duration of lurbinectedin-induced nausea can vary, it appears that it can be prolonged, with some patients experiencing symptoms for several days after treatment. Sources: [1] https://pubmed.ncbi.nlm.nih.gov/33511653/ [2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214444s000lbl.pdf [3] https://www.drugpatentwatch.com/
Other Questions About Lurbinectedin :